Last update 01 Nov 2024

BioGeneric Pharma SAE

Private Company|
2005|
Egypt
|
www.biogenericpharma.com

Overview

Tags

Hemic and Lymphatic Diseases
Neoplasms
Urogenital Diseases
Biosimilar
Interferons
Interleukins

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases3
Neoplasms3
Infectious Diseases2
Endocrinology and Metabolic Disease1
Immune System Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Biosimilar7
Interferons2
Interleukins2
Hormone2
Colony-stimulating factors1
Top 5 TargetCount
IFNAR(Interferon alpha/beta receptor)2
CSF-2R(Granulocyte-macrophage colony-stimulating factor receptor)1
GHR(Growth hormone receptor)1
IL-2R(Interleukin-2 receptor)1
FSHR(Follicle-stimulating hormone receptor)1

Related

10
Drugs associated with BioGeneric Pharma SAE
YPEG-interferon alfa-2a(Amoytop Biotech)
Target
IFNα2
Mechanism
IFNα2 stimulants [+1]
Active Org.-
Originator Org.
Xiamen Amoytop Biotech Co. Ltd.Xiamen Amoytop Biotech Co. Ltd.
Active Indication-
Inactive Indication
Hepatitis B [+1]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
Recombinant interferon gamma(Xiamen Amoytop Biotech Co. Ltd.)
Target
IFNγ
Mechanism
IFNγ stimulants [+1]
Active Org.-
Originator Org.
Xiamen Amoytop Biotech Co. Ltd.Xiamen Amoytop Biotech Co. Ltd.
Active Indication-
Inactive Indication-
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
Erythropoietin(Xiamen Amoytop Biotech Co. Ltd.)
Target
EPO receptor
Mechanism
EPO receptor agonists [+1]
Active Org.-
Originator Org.
Xiamen Amoytop Biotech Co. Ltd.Xiamen Amoytop Biotech Co. Ltd.
Active Indication-
Inactive Indication
Anemia [+4]
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with BioGeneric Pharma SAE
NCT01327729 / Unknown statusPhase 2/3
Clinical Trial of the Efficacy, Dosing, Safety and Tolerability of Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
100 Clinical Results associated with BioGeneric Pharma SAE
Login to view more data
0 Patents (Medical) associated with BioGeneric Pharma SAE
Login to view more data
100 Deals associated with BioGeneric Pharma SAE
Login to view more data
100 Translational Medicine associated with BioGeneric Pharma SAE
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
6
4
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free